Mocetinostat

Search with Google Search with Bing

Information
Drug Name
Mocetinostat
Description
Entry(CIViC)
1
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
malignant mesothelioma BAP1 MUTATION BAP1 MUTATION E Predictive Supports Sensitivity/Response Somatic 2 25970771 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
A siRNA screen identified BAP1 associated with HDA... BAP1 BAP1 MUTATION BAP1 MUTATION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT03220477 Active, not recruiting Phase 1 Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer. August 4, 2017 July 2024
NCT02236195 Completed Phase 2 Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes October 2014 July 2016
NCT02018926 Completed Phase 1/Phase 2 Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS December 2013 September 2015
NCT02303262 Completed Phase 2 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma November 12, 2015 December 2016
NCT04299113 Recruiting Phase 1 Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma May 14, 2020 May 22, 2026
NCT02954991 Terminated Phase 2 Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer November 7, 2016 November 4, 2021
NCT02282358 Terminated Phase 1/Phase 2 Study of Mocetinostat in Selected Patients With Mutations of Acetyltransferase Genes in Relapsed and Refractory Diffuse Large B-Cell Lymphoma and Follicular Lymphoma October 2014 May 26, 2023
NCT02993991 Withdrawn Phase 1 Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity October 10, 2017 December 21, 2017